Combined Biologic Therapy in 2 Patients With Severe Psoriasis and Severe Atopic Dermatitis

M. Pascual Ares A. Orbea Sopeña A. Aramburu González J. Gardeázabal García

PII: S0001-7310(24)00199-6
DOI: https://doi.org/doi:10.1016/j.ad.2024.03.011
Reference: AD 3897
To appear in: Actas dermatosifiliográficas
Received Date: 19 September 2022
Accepted Date: 28 January 2023

Please cite this article as: Pascual Ares M, Orbea Sopeña A, Aramburu González A, Gardeázabal García J. [Translated article] Combined Biologic Therapy in 2 Patients With Severe Psoriasis and Severe Atopic Dermatitis. Actas dermatosifiliográficas (2024), doi:https://doi.org/10.1016/j.ad.2024.03.011

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier.
Refers to AD_3682

Carta científico-clínica

Tratamiento biológico combinado en 2 pacientes con psoriasis y dermatitis atópica graves

[[Translated article]Combined Biologic Therapy in 2 Patients With Severe Psoriasis and Severe Atopic Dermatitis

Autores:

M. Pascual Aresª, A. Orbea Sopeñaª, A. Aramburu Gonzálezª y J. Gardeazábal Garcíaª

ª Servicio de Dermatología, Hospital Universitario Cruces, Barakaldo (Bizkaia), España

* Autor para correspondencia.

Correo electrónico: manuel.pascualares@osakidetza.eus

To the Editor,

Biologic therapies have revolutionized the management of psoriasis and atopic dermatitis. Traditionally, it has been understood that the pathogenic mechanisms of both diseases are different (mediated by Th1 lymphocytes in psoriasis and Th2 lymphocytes in atopic dermatitis). However, some patients exhibit both conditions concomitantly, usually in mild forms, being severe forms exceptional and difficult to treat.1-3 We present 2 cases with this exceptionally rare association and their progression with 2 biologic therapies.

Patient #1 is a 50-year-old man with a family history of psoriasis (father), and a personal history of rhinitis, asthma, and schizophrenia, which remained under control with carbamazepine, clonazepam, and risperidone. He also had a 30-year history of severe atopic dermatitis (figure 1a). Over the years, he had been on multiple treatments, both topical (corticosteroids and tacrolimus), and systemic (oral prednisone, phototherapy, methotrexate,
and cyclosporine) for his dermatitis with partial atopic symptom relief. Before starting dupilumab, he had a SCORAD score of 59. Three years before starting the dual treatment, he was prescribed dupilumab at standard doses, which significantly improved his skin lesions. One year later, following a decompensation of his psychiatric condition, his diagnosis was changed to bipolar disorder, and he was put lithium therapy. Coinciding with the initiation of this drug, the patient started developing extensive psoriatic lesions primarily affecting his face, neck, and upper limbs, with a PASI score of 16 and a BSA of 13 (figure 1b). After ruling out drug interactions, cyclosporine was added to the dupilumab therapy, resulting in significant improvement, but also relapses of psoriasis each time the dose of cyclosporine would be down-titrated. After 18 months on this treatment, cyclosporine was discontinued, and guselkumab was initiated to keep psoriasis under control, with a good response to the new drug. After more than a year on combined biologic therapy (guselkumab + dupilumab), the patient is now free of active lesions from both conditions and no adverse events have been reported (figures 1c and d).

Patient #2 is a 41-year-old man with severe psoriasis since adolescence and a 7-year history of severe atopic dermatitis as confirmed by biopsy. He also had morbid obesity (170 kg with a BMI of 58) as a comorbidity. He had been treated with topical and systemic corticosteroids, methotrexate, azathioprine, cyclosporine, and phototherapy, without achieving good control of either disease (figure 2a). Four years before starting the dual therapy, he experienced a new psoriasis flare-up, mostly psoriasiform in nature, with a PASI of 35, a BSA of 84, and a SCORAD score of 23. He started therapy with ustekinumab, which initially improved the psoriasis component but later lost its effectiveness. Subsequently, he was treated with ixekizumab and then with guselkumab plus azathioprine, achieving good psoriasis control but poor atopic dermatitis control. Azathioprine was discontinued, and he was put on dupilumab. After 10 months of combined biologic therapy (guselkumab + dupilumab), the patient’s psoriasis remains under control (PASI 7 and BSA 7), unlike his atopic dermatitis (SCORAD 85 and NRS 8) (figures 2b and c).

Psoriasis and atopic dermatitis are 2 highly prevalent inflammatory skin diseases.2,4 Recent publications suggest that there are common pathogenic pathways in both diseases mediated by Th1 and Th17 lymphocytes.1 Very few articles have been published on the management of severe psoriasis and atopic dermatitis. In fact, we only found 1 report on a series of 6 patients with both conditions treated with 2 biologic drugs (dupilumab and guselkumab) simultaneously. In this review, 1 patient had no active lesions, 4 had improved both of their conditions, and only 1 had improved the atopic component with this therapy. No significant adverse events were reported in any of these patients.5 Following the publication of this review, we decided to initiate combined treatment with dupilumab and guselkumab in these 2 patients. In addition, a literature search was conducted on the efficacy of JAK inhibitors in the management of these conditions as a possible therapeutic target that interferes with the pathogenic pathways of both diseases. The use of these drugs was discarded due to their limited effectiveness in the management of severe psoriasis.6,7 We presented our own experience with a dual biologic therapy in 2 patients with an exceptionally rare association of severe psoriasis and atopic dermatitis. In our cases, patient #1 achieved control of both conditions at the 12-month follow-up, remaining asymptomatic and without adverse events. At the 10-month follow-up, patient #2 achieved good control of the psoriasiform component,
but poor control of the atopic one, possibly due to his obesity, without any adverse events being reported. The main limitation of this clinical note is that the diagnosis of psoriasis in patient #1 was clinical and was established without lesion biopsy. Due to the limited published literature in this area, long-term monitoring of these patients is needed to assess the safety and efficacy of the combination of both drugs.

Conflicts of interest

None declared.
References

1
S Guttman-Yassky F E.
S Krueger F J.G.
S Lebwohl F M.G.
AT Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment
JT Exp Dermatol.
V 27
D 2018
P 409-L 417
IR http://dx.doi.org/10.1111/exd.13336

2
S Cunliffe F A.
S Gran F S.
S Ali F U.
S Grindlay F D.
S Lax F S.J.
S Williams F H.C.<ET-AL>
AT Can atopic eczema and psoriasis coexist? A systematic review and meta-analysis
JT Ski Heal Dis.
V 1
D 2021
P e29
IR http://dx.doi.org/10.1002/ski2.29

3
S Barry F K.
S Zancanaro F P.
S Casseres F R.
S Abdat F R.
S Dumont F N.
S Rosmarin F D.

AT Concomitant atopic dermatitis and psoriasis - a retrospective review
JT J Dermatolog Treat.
V 32
D 2021
P 716-L 720
IR http://dx.doi.org/10.1080/09546634.2019.1702147

4
S Bozek F A.
S Zajac F M.
S Krupka F M.

AT Atopic dermatitis and psoriasis as overlapping syndromes
JT Mediators Inflamm.
V 2020
D 2020
P 7527859
IR http://dx.doi.org/10.1155/2020/7527859

5
S Barry F K.
S Zancanaro F P.
S Casseres F R.
S Dumont F N.
S Rosmarin F D.

AT A retrospective review of dupilumab and psoriasis biologic combination therapy
JT J Dermatolog Treat.
V 32
D 2021
P 438-L 439
AT Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2 randomized placebo-controlled dose-ranging study

JT Br J Dermatol.
V 167
D 2012
P 668-L 677

AT A randomized phase 2 trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

JT Br J Dermatol.
V 174
D 2016
P 1266-L 1276
Figure 1 a) Eczematous lesions with significant face involvement. b) Extensive psoriatic lesions mainly affecting the face, neck, and upper limbs after starting lithium therapy. c) No active lesions were reported after more than a 1 year on guselkumab + dupilumab. d) Treatment timeline.
Paciente nº2

<table>
<thead>
<tr>
<th>Año</th>
<th>Evento</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Inicio de Ustekinumab en píleo habitual</td>
</tr>
<tr>
<td>06/2017</td>
<td>Stop Ustekinumab + Acitretina</td>
</tr>
<tr>
<td>02/2019</td>
<td>Stop Ustekinumab + Inicio de Gwifukumab</td>
</tr>
<tr>
<td>04/2021</td>
<td>Stop Acitretina</td>
</tr>
<tr>
<td></td>
<td>Se inicia Gwifukumab</td>
</tr>
<tr>
<td></td>
<td>Se inicia Duplikumab según píleo habitual</td>
</tr>
<tr>
<td></td>
<td>Tras diez meses</td>
</tr>
</tbody>
</table>

PASI 7 BSA 7  
SCORAD 85 NRS 8
Figure 2  a) Eczematous and psoriasiform lesions with widespread involvement. b) Good psoriasis control, and poor atopic dermatitis control after a 10-month course on guselkumab + dupilumab. c) Treatment timeline.

TRADUCCIÓN DE FIGURAS
(COLOR NEGRO: ESPAÑOL · COLOR AZUL: INGLÉS)

Figura 1

Paciente nº 1
Patient #1
Tacrolimus tópico
Topical tacrolimus
Corticoides tópicos
Topical corticosteroids
Corticoides orales
Oral corticosteroids
Brote: Metotrexate 20 mgs/semana
Flare-up: methotrexate 20 mg/week
Inicio Dupilumab 300 mgs sc/2 sem
Initiation of subcutaneous dupilumab 300 mg every 2 weeks
Diagnóstico de psoriasis: inicio ciclosporina+dupilumab
Diagnosis of psoriasis: Initiation of cyclosporine + dupilumab
Dupilumab 300 mgs/2 sem
Dupilumab 300 mg every 2 weeks
Guselkumab según pauta habitual
Guselkumab per standard regimen
Tras más de un año
After more than a year
Tratamiento concomitante por esquizofrenia: carbamezepina, clonazepam y risperidone
Concomitant treatment for schizophrenia: carbamazepine, clonazepam, and risperidone

UVBBE
NB-UBV

Corticoides tópicos
Topical corticosteroids

Corticoides orales
Oral corticosteroids

Brote: Metotrexate 20 mg/sem. + Prednisona oral
Flare-up: methotrexate 20 mg/week + oral prednisone

Inicio Litio por cambio diagnóstico a trastorno bipolar
Initiation of lithium due to a change in diagnosis to bipolar disorder

Stop ciclosporina
Discontinuation of cyclosporine

Se mantiene dupilumab
Continuation of dupilumab

Se inicia Gusekumab
Initiation of gusekumab

Sin lesiones activas
No active lesions

Figura 2

Paciente nº 2
Patient #2

Inicio de Ustekinumab según pauta habitual
Initiation of ustekinumab per standard regimen

Stop Ixekizumab
Discontinuation of ixekizumab
Inicio Guselkumab + Azatioprina
Initiation of guselkumab + azathioprine
Dupilumab 300 mgs/2 sem
Dupilumab 300 mg every 2 weeks
Guselkumab según pauta habitual
Guselkumab per standard regimen
Tras diez meses
After 10 months
Corticoides tópicos
Topical corticosteroids
Corticoides sistémicos
Systemic corticosteroids
Metotrexate
Methotrexate
Ciclosporina
Cyclosporine
Fototerapia
Phototherapy
Azatioprina
Azathioprine
Stop Ustekinumab
Discontinuation of ustekinumab
Inicio de Ixekizumab según pauta habitual
Initiation of iekizumab per standard regimen
Stop Azatioprina
Discontinuation of azathioprine
Se mantiene Guselkumab
Continuation of guselkumab
Se inicia Dupilumab según pauta habitual
Initiation of dupilumab per standard regimen
PASI 7
PASI 7
BSA 7
BSA 7
SCORAD 85
SCORAD 85
NRS 8
NRS 8